- Gut dysfunction may be one of the biggest drivers of MCAS symptoms, especially when SIBO or IBS are present.
- Low-histamine, low-FODMAP, and elemental diets may help calm mast cell activation by reducing immune and fermentation triggers.
- Probiotics, quercetin, vitamin C, and other natural compounds may support mast cell stability when used alongside gut-focused treatment.
- Most people with MCAS need a layered treatment approach that combines diet, gut repair, antihistamines, and trigger reduction.
- Emerging research suggests GLP-1 receptor agonists may help reduce inflammation and mast cell reactivity in treatment-resistant cases.
- Progress in MCAS is often gradual. Improvements in flare frequency, food tolerance, and daily function matter more than perfection.
Mast cell activation syndrome (MCAS) can feel like the body is suddenly reacting to everything. Foods, stress, temperature changes, supplements, smells, and even healthy habits may trigger symptoms like flushing, hives, digestive issues, brain fog, anxiety, or fatigue.
One of the most frustrating parts of MCAS is how difficult it can be to identify what’s actually driving the problem. Many people end up cycling through restrictive diets, supplements, and medications without a clear strategy tying everything together.
In my experience, the best MCAS treatment approach is usually layered: reducing triggers, improving gut health, stabilizing mast cells, and lowering the body’s overall inflammatory burden.
In this article, I’ll walk through the treatment strategies I’ve found most helpful, including diet, gut healing, antihistamines, natural mast cell support, and promising emerging therapies like GLP-1 receptor agonists.
Step 1: Identify and Avoid Your Triggers
The foundation of MCAS treatment is identifying what’s consistently activating mast cells in the first place.
Triggers vary widely from person to person, but common ones include 1:
- Alcohol (including alcohol found in hand sanitizers and cleaning products)
- High-histamine foods
- Stress
- Mold exposure
- Heat or cold
- Fragrances and chemicals
- Certain medications
- Infections
- Overexertion
- Sleep deprivation
- Irritation from clothing (such as clothes that are too tight or itchy fabric)
- Bug bites or allergic reactions
For some people, reducing trigger load alone significantly improves symptoms. Others need a more layered approach.
One important mindset shift: Treatment is rarely about achieving a perfectly “clean” environment or diet. The goal is to improve resilience and reduce the overall inflammatory burden enough that the nervous and immune systems become less reactive over time.
Keeping a simple symptom journal can help identify patterns, especially around food, stress, sleep, and environmental exposures.
Step 2: Heal Your Gut
If there’s one area of MCAS treatment I think is consistently underappreciated, it’s gut health.
The gastrointestinal tract is one of the most mast-cell-dense tissues in the body, and gut dysfunction doesn’t just coexist with MCAS; it may actively drive it.
Research shows:
- Irritable bowel syndrome (IBS) is associated with a 16-times greater risk of MCAS 2
- Small intestinal bacterial overgrowth (SIBO) may be roughly three times more common in people with MCAS than in healthy controls
- High-FODMAP diets may worsen mast cell activity by increasing fermentation and gut permeability 3
- Low-FODMAP diets have been shown to significantly reduce histamine levels in some patients 4
In clinical practice, this connection is hard to ignore.
When bacteria overgrow in the small intestine, fermentation byproducts may trigger immune activation, increase histamine signaling, and perpetuate mast cell reactivity. Addressing the gut often helps calm the entire system.
| WHAT THE RESEARCH SHOWS SIBO is three times more common in people with MCAS than in healthy people. And IBS, the most common functional gut disorder, is associated with a 16-times greater risk of MCAS. When there’s too much bacteria in the small intestine, the byproducts of fermentation trigger immune reactivity and increase mast cell firing. Addressing the gut often calms the whole system. (Weinstock et al., 2019; Kurin et al., 2022) |
Choosing a Dietary Approach
Not everyone with MCAS needs the same diet. I typically start with a whole-foods foundation, like a Paleo or Mediterranean-style approach, then layer in targeted restrictions depending on symptom patterns.
- Low-histamine diet: This approach works best when symptoms are clearly linked to histamine-rich foods like fermented foods, aged cheeses, wine, leftovers, avocado, and spinach. The goal is to reduce the total histamine burden the body has to process.
- Low-FODMAP diet: This is often more helpful when IBS-type symptoms dominate, especially bloating, gas, diarrhea, and cramping. Reducing fermentable carbohydrates lowers bacterial fermentation in the gut, which may reduce mast cell activation and histamine production.
- Elemental diet: For severe or highly reactive cases, an elemental diet may help reset the gut immune environment by providing fully or partially broken-down nutrition with minimal digestive demand. This can be especially useful for people reacting to many foods or struggling with persistent SIBO.
Cooking note: Histamine levels increase with frying and grilling but remain stable or decrease with boiling. Simple swaps in cooking methods can meaningfully reduce dietary histamine load 5.
Treating SIBO if Present
Because SIBO is so common in MCAS, it’s worth evaluating and treating directly when present.
Bacterial overgrowth in the small intestine produces fermentation byproducts that may perpetuate immune activation and histamine release. In some people, treating SIBO produces broader symptom improvement than antihistamines alone.
| CLINICAL OBSERVATION Some people, when they’re trying to improve their health, go ‘all right, healthy fruits and vegetables and lots of fiber.’ And they go on this healthy diet kick. Inadvertently, they go really high FODMAP when they do that. And they go, ‘Doc, I’m doing everything to improve my gut health and I’m feeling worse.’ Reducing FODMAPs reduces the food for those bacteria. That overgrowth is no longer triggering the immune system. And we can see a normalization of histamine levels when we do that.— Dr. Michael Ruscio, DC (Mast Cell Matters Podcast with Dr. Tania Dempsey) |
Want to go deeper on SIBO?
If your symptoms suggest small intestinal bacterial overgrowth may be a factor, we’ve put together a comprehensive guide covering SIBO: how it develops, how it’s tested, and the most effective treatment approaches. It’s a natural next step if gut dysfunction is at the center of your picture.
Step 3: Natural Mast Cell Support
Once diet and gut work are underway, certain supplements may help further stabilize mast cells and reduce histamine reactivity.
I view these as supportive tools rather than standalone solutions, but in the right person, they may meaningfully improve symptom control.
Probiotics
Probiotics are one of the more overlooked tools in MCAS support.
While direct human data on MCAS is still limited, probiotics have been shown to reduce histamine-related symptoms in seasonal allergies, and experimental research suggests that certain strains may help regulate mast cell signaling 6.
In practice, supporting the microbiome while addressing SIBO and diet is often among the most productive approaches.
Quercetin
Quercetin is a plant flavonoid found in foods like apples and onions that has shown mast-cell-stabilizing effects in experimental research 7 8.
It appears to reduce histamine release, inflammatory signaling, and mast cell activation pathways. Human trials remain limited, but the overall safety profile and mechanistic rationale are strong.
Supplementing with quercetin is typically at doses ranging from 500–1,000 mg daily.
Vitamin C
Vitamin C is a potent antioxidant and antihistamine 9.
It’s vital for maintaining a balanced immune system. Optimal vitamin C intake, through diet or supplementation when necessary, has been shown to reduce inflammation and improve health outcomes in some allergic diseases 10.
Other Supportive Compounds
Additional compounds with emerging evidence for mast cell support include:
One important consideration: Many people with MCAS are highly sensitive to fillers, dyes, and capsule ingredients. Starting low and slow with high-quality formulations that have limited additives is often important for tolerability.
Step 4: Antihistamines and Medications
When diet, gut work, and supplements aren’t enough, medications become an important part of treatment.
The goal is to reduce the inflammatory effects of mast cell mediators while stabilizing the mast cells themselves.
H1 Antihistamines
H1 antihistamines are usually the first-line medication approach for symptoms like 17 18:
- Itching
- Hives
- Flushing
- Brain fog
Second-generation antihistamines like cetirizine (Zyrtec), loratadine (Claritin), and fexofenadine (Allegra) are generally preferred because they cause less sedation.
H2 Antihistamines
H2 receptors are concentrated heavily in the digestive tract.
Medications like famotidine (Pepcid) may help reduce 17 18:
- Reflux
- Cramping
- Nausea
- Abdominal discomfort
Many MCAS patients benefit from using both H1 and H2 antihistamines together 17.
Mast Cell Stabilizers
Where antihistamines block the effects of mediators after release, mast cell stabilizers work upstream, helping prevent degranulation in the first place.
- Cromolyn sodium (oral): Primarily targets gut mast cells, and it may be the most useful for GI-dominant MCAS, particularly when H1 and H2 antihistamines are not helping gut symptoms. It is typically recommended to start with a low dose and work up to 200 mg four times daily on an empty stomach 17. Many people report broader symptom improvement despite its poor systemic absorption.
- Ketotifen: A dual-action antihistamine and mast cell stabilizer. Particularly helpful for itch and nighttime symptoms, but it can cause drowsiness and sleepiness. Over-the-counter (OTC) eye drops are available for eye symptoms, but oral formulations require compounding in the US 18.
Leukotriene Inhibitors
Leukotrienes are inflammatory mediators released alongside histamine during mast cell degranulation. Montelukast (Singulair) blocks their receptors and is particularly useful for respiratory symptoms, skin inflammation, and conditions overlapping with asthma or eczema.
For Severe or Refractory Cases
- Omalizumab (Xolair): An anti-IgE biologic that reduces mast cell surface IgE receptors, lowering overall mast cell sensitivity. Used for severe, poorly controlled MCAS or when anaphylaxis risk is high.
- Low-dose aspirin: May help when prostaglandin-mediated symptoms (flushing, GI symptoms) predominate, but use cautiously as some MCAS patients react to aspirin.
- Corticosteroids: Reserved for acute severe reactions and short-term use only. Not appropriate for long-term MCAS management due to side effect profile.
Step 5: Emerging Therapies—Including GLP-1 Receptor Agonists
For patients who’ve worked through the steps above and still aren’t getting adequate relief, the research is beginning to open some genuinely exciting new doors.
GLP-1 Receptor Agonists
One of the more interesting emerging areas in MCAS treatment involves GLP-1 receptor agonists 19.
These medications were originally developed for type 2 diabetes and weight management, but researchers are now exploring their broader anti-inflammatory effects.
The biology is compelling: Mast cells express GLP-1 receptors on their surface, meaning these medications may directly influence mast cell signaling and inflammatory pathways.
| WHAT THE RESEARCH SHOWS A landmark 2025 case series (Afrin, Weinstock, Dempsey et al.) followed 47 patients with treatment-resistant MCAS, patients who had not responded adequately to conventional therapies. Among them, 89% experienced clinical benefit with GLP-1 receptor agonists, often within hours to days, across inflammatory, neurologic, gastrointestinal, and autonomic symptoms. The authors called for rigorous clinical trials to define their role. – Afrin et al., Am J Med Sci, 2025 |
This is still early research, but it’s one of the more promising developments I’ve seen in this area in quite some time.
Some clinicians are now exploring lower-dose GLP-1 protocols designed to leverage potential anti-inflammatory benefits while minimizing the side effects more commonly associated with weight-loss dosing.
Other Emerging Options
- Low-dose naltrexone (LDN): Transiently blocks opioid receptors to upregulate natural endorphins and support immune regulation. Used off-label in MCAS and other inflammatory conditions with growing anecdotal and preliminary clinical support 20.
- Masitinib: A tyrosine kinase inhibitor targeting the KIT receptor on mast cells. FDA fast-track designation was granted for MCAS in 2021. Clinical trials are ongoing 21.
- Diamine oxidase (DAO) supplementation: Supports the body’s own histamine-degrading enzyme activity. Particularly relevant for patients whose MCAS overlaps with histamine intolerance.
How to Know if Your Treatment Is Working
Progress in MCAS is often gradual and non-linear. Here are practical markers to track:
- Flare frequency: Are episodes happening less often, even if they’re still intense when they occur?
- Flare severity: When you do react, does it resolve faster or feel less overwhelming?
- Food tolerance: Are you able to eat a wider variety of foods without triggering symptoms?
- Baseline function: Are you sleeping better, thinking more clearly, or able to do more in a day?
- Trigger threshold: Does it take more to set off a reaction than it used to?
Many people expect improvement to feel dramatic and immediate, but more often it looks like slowly regaining resilience over time.
One important clinical principle: If you have been following the same protocol for a year or more without meaningful improvement, it’s worth reassessing the strategy. The root driver may not be where you think it is.
MCAS Treatment FAQs
What is the best treatment for MCAS?
The best MCAS treatment usually combines trigger reduction, dietary therapy, gut healing, antihistamines, and mast cell stabilization. Most people improve best with a layered approach rather than a single medication or supplement.
Can gut health affect MCAS?
Yes. IBS and SIBO appear to be significantly more common in people with MCAS, and gut dysfunction may directly contribute to mast cell activation and histamine release.
What foods should you avoid with MCAS?
Common triggers include alcohol, fermented foods, processed meats, leftovers, aged cheeses, and other high-histamine foods. Some people also react strongly to high-FODMAP foods.
Can you live a normal life with MCAS?
Yes. MCAS is a chronic condition that requires ongoing management, but it is not progressive in the way many serious diseases are. With the right combination of trigger reduction, gut-focused treatment, and appropriate medications, most people experience meaningful improvement in symptoms and daily function. Many patients go from being unable to tolerate basic activities to living full, active lives.
Bottom Line
MCAS treatment works best when the focus shifts from simply suppressing symptoms to calming the underlying immune instability driving them.
For many people, that means looking beyond antihistamines alone and addressing gut dysfunction, microbial overgrowth, food triggers, stress load, and overall inflammatory burden together.
And while emerging therapies like GLP-1 receptor agonists are opening exciting new possibilities, the fundamentals still matter most: improving gut health, stabilizing mast cells, reducing triggers, and rebuilding resilience over time.
If you need guidance figuring out where to start, we’re here to help. You can book a consultation right online.
Dr. Michael Ruscio is a DC, natural health provider, researcher, and clinician. He serves as an Adjunct Professor at the University of Bridgeport and has published numerous papers in scientific journals as well as the book Healthy Gut, Healthy You. He also founded the Ruscio Institute of Functional Health, where he helps patients with a wide range of GI conditions and serves as the Head of Research.
➕ References
- Jennings SV, Slee VM, Finnerty CC, Hempstead JB, Bowman AS. Symptoms of mast cell activation: The patient perspective. Ann Allergy Asthma Immunol. 2021 Oct;127(4):407–9. DOI: 10.1016/j.anai.2021.07.004. PMID: 34271184.
- Kurin M, Elangovan A, Alikhan MM, Al Dulaijan B, Silver E, Kaelber DC, et al. Irritable bowel syndrome is strongly associated with the primary and idiopathic mast cell disorders. Neurogastroenterol Motil. 2022 May;34(5):e14265. DOI: 10.1111/nmo.14265. PMID: 34535952. PMCID: PMC9191257.
- Singh P, Grabauskas G, Zhou S-Y, Gao J, Zhang Y, Owyang C. High FODMAP diet causes barrier loss via lipopolysaccharide-mediated mast cell activation. JCI Insight. 2021 Nov 22;6(22). DOI: 10.1172/jci.insight.146529. PMID: 34618688. PMCID: PMC8663790.
- McIntosh K, Reed DE, Schneider T, Dang F, Keshteli AH, De Palma G, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017 Jul;66(7):1241–51. DOI: 10.1136/gutjnl-2015-311339. PMID: 26976734.
- Chung BY, Park SY, Byun YS, Son JH, Choi YW, Cho YS, et al. Effect of different cooking methods on histamine levels in selected foods. Ann Dermatol. 2017 Dec;29(6):706–14. DOI: 10.5021/ad.2017.29.6.706. PMID: 29200758. PMCID: PMC5705351.
- Herrera-Saldivar MF, Hernandez-Bautista NC, Quiroga-Garza JM, Vazquez-Guillen JM, Chacon-Salinas R, Rojas-Contreras M, et al. The interplay between probiotics and mast cells in gut inflammation: a mini-review. Front Cell Infect Microbiol. 2026 Apr 1;16:1772010. DOI: 10.3389/fcimb.2026.1772010. PMID: 41994207.
- Su P, Li Z, Yan X, Wang B, Bai M, Li Y, et al. Quercetin and Kaempferol inhibit HMC-1 activation via SOCE/NFATc2 signaling and suppress hippocampal mast cell activation in lipopolysaccharide-induced depressive mice. Inflamm Res. 2024 Jun;73(6):945–60. DOI: 10.1007/s00011-024-01876-7. PMID: 38587532.
- Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS ONE. 2012 Mar 28;7(3):e33805. DOI: 10.1371/journal.pone.0033805. PMID: 22470478. PMCID: PMC3314669.
- Ghalibaf MHE, Kianian F, Beigoli S, Behrouz S, Marefati N, Boskabady M, et al. The effects of vitamin C on respiratory, allergic and immunological diseases: an experimental and clinical-based review. Inflammopharmacology. 2023 Apr;31(2):653–72. DOI: 10.1007/s10787-023-01169-1. PMID: 36849854. PMCID: PMC9970132.
- Trincianti C, Naso M, Tosca MA, Ciprandi G. Vitamin C in allergy mechanisms and for managing allergic diseases: A narrative review. Children (Basel). 2025 May 30;12(6). DOI: 10.3390/children12060718. PMID: 40564676.
- Tsilioni I, Theoharides T. Luteolin Is More Potent than Cromolyn in Their Ability to Inhibit Mediator Release from Cultured Human Mast Cells. Int Arch Allergy Immunol. 2024 Apr 8;185(8):803–9. DOI: 10.1159/000537752. PMID: 38588651.
- Wang X, Ma DWL, Kang JX, Kulka M. n-3 Polyunsaturated fatty acids inhibit Fc ε receptor I-mediated mast cell activation. J Nutr Biochem. 2015 Dec;26(12):1580–8. DOI: 10.1016/j.jnutbio.2015.07.027. PMID: 26363927.
- Liu ZQ, Li XX, Qiu SQ, Yu Y, Li MG, Yang LT, et al. Vitamin D contributes to mast cell stabilization. Allergy. 2017 Aug;72(8):1184–92. DOI: 10.1111/all.13110. PMID: 27998003.
- Mehrani Y, Morovati S, Tieu S, Karimi N, Javadi H, Vanderkamp S, et al. Vitamin D Influences the Activity of Mast Cells in Allergic Manifestations and Potentiates Their Effector Functions against Pathogens. Cells. 2023 Sep 14;12(18). DOI: 10.3390/cells12182271. PMID: 37759494. PMCID: PMC10528041.
- Zhang N, Li H, Jia J, He M. Anti-inflammatory effect of curcumin on mast cell-mediated allergic responses in ovalbumin-induced allergic rhinitis mouse. Cell Immunol. 2015 Sep 28;298(1–2):88–95. DOI: 10.1016/j.cellimm.2015.09.010. PMID: 26507910.
- Yacoub M-R, Ramirez GA, Berti A, Mercurio G, Breda D, Saporiti N, et al. Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study. Int Arch Allergy Immunol. 2018 Apr 26;176(3–4):268–71. DOI: 10.1159/000488142. PMID: 29698966.
- Lee E, Picard M. Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach. Allergy Asthma Clin Immunol. 2025 Nov 21;21(1):49. DOI: 10.1186/s13223-025-00998-9. PMID: 41272881.
- Akin C, Butterfield JH, Castells M, Lyons JJ. Management of indolent mastocytosis and mast cell activation syndrome: A clinical yardstick. Ann Allergy Asthma Immunol. 2025 Oct;135(4):466–77. DOI: 10.1016/j.anai.2025.06.032. PMID: 40592381.
- Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S, Schofield JR. Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. Am J Med Sci. 2025 Oct;370(4):377–82. DOI: 10.1016/j.amjms.2025.07.006. PMID: 40675372.
- Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018 Jan 11;2018. DOI: 10.1136/bcr-2017-221405. PMID: 29326369. PMCID: PMC5778345.
- AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS) – AB Science [Internet]. [cited 2026 May 29]. Available from: https://www.ab-science.com/ab-science-receives-fda-authorization-to-start-clinical-development-program-of-masitinib-in-mast-cell-activation-syndrome-mcas/
➕ Links & Resources
Discussion
I care about answering your questions and sharing my knowledge with you. Leave a comment or connect with me on social media asking any health question you may have and I just might incorporate it into our next listener questions podcast episode just for you!